Nalmefene (Selincro®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32014000450
English
Authors' recommendations:
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA325) NICE GUIDANCE ISSUED NOVEMBER 2014
Nalmefene (Selincro®) is recommended as an option for use within NHS Wales for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL) without physical withdrawal symptoms and who do not require immediate detoxification. Nalmefene should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption. Nalmefene should be initiated only in patients who continue to have a high DRL two weeks after initial assessment.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/1259
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Naltrexone
- Narcotic Antagonists
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.